Diagnosis and Treatment Strategy Optimization of Severe Pneumonia Based on Multi-omics Data Integration

NCT06288074 | Recruiting

• 1 other identifier: SF-2022-1-1061
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

Severe community-acquired pneumonia still has a high incidence and mortality, but the molecular mechanism and prognostic biomarkers of severe community-acquired pneumonia caused by different pathogens are still unclear, and the best treatment strategy has not been determined. Based on this, this project intends to take patients with severe community-acquired pneumonia caused by different pathogens as the research object, explore the molecular mechanism of severe community-acquired pneumonia from multiple angles, integrate relevant research data to evaluate the rationality of initial empirical medication, and lay the foundation for precise treatment of severe pneumonia. The research results will help to develop a new rapid and accurate target for clinical diagnosis and efficacy evaluation of severe pneumonia, and build a precise treatment system for severe pneumonia.

Conditions

Severe Community-acquired Pneumonia

Outcome Measures

Primary Outcomes (1)

• Hospital mortality

  during hospitalization (up to day 14)

Secondary Outcomes (4)

• Cause of death

  during hospitalization (up to day 14)

• Length of stay

  during hospitalization (up to day 14)

• Length of ICU stay

  during hospitalization (up to day 14)

• Expense during hospitalization

  during hospitalization (up to day 14)

Study Arms (3)

Severe community-acquired pneumonia

Diagnostic Test: Multi-omics tests

Non-Severe community-acquired pneumonia

Diagnostic Test: Multi-omics tests

Healthy control

Diagnostic Test: Multi-omics tests

Interventions

Multi-omics tests DIAGNOSTIC_TEST

Biological sample collection for Multi-omics tests

Healthy control; Non-Severe community-acquired pneumonia; Severe community-acquired pneumonia

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

A prospective cohort including 100 patients with severe and 100 patients with non-severe community-acquired pneumonia and 100 healthy people was selected.

You may qualify if:

• Age\> 18 years old
• Clinical diagnosis of community-acquired pneumonia

You may not qualify if:

• Pregnancy, perinatal and lactating women
• Combined immunosuppressive diseases: such as HIV, solid organ transplantation, solid organ/hematologic malignant tumor chemotherapy, rheumatic diseases or glomerular diseases need to take hormone/immunosuppressant therapy
• Combined blood system diseases: such as leukemia reactions, aplastic anemia, neutropenia or deficiency of granulocytes, previous bone marrow/stem cell transplantation

Sponsors & Collaborators

• Capital Medical University: lead

Study Sites (1)

Beijing Institute of Respiratory Medicine

Beijing, Beijing Municipality, 100027, China

RECRUITING

MeSH Terms

Conditions

Community-Acquired Pneumonia

Condition Hierarchy (Ancestors)

Community-Acquired Infections; Infections; Pneumonia; Respiratory Tract Infections; Respiratory Tract Diseases

Central Study Contacts

Zhaohui Tong, Dr

CONTACT

+86 139 1093 0309; 13910930309@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor

Study Record Dates

• First Submitted: January 3, 2024
• First Posted: March 1, 2024
• Study Start: March 10, 2024
• Primary Completion: December 31, 2024
• Study Completion: December 31, 2024
• Last Updated: March 1, 2024

Record last verified: 2024-02

Data Sharing

• IPD Sharing: Will share

Locations

CN (1)